Thomas D. Geracioti

Phase 2 Discovery, Inc. (P2D) develops central nervous system drugs. The company provides discovery research & development services for pharmaceutical and biotechnology companies. It also develops drugs for treating psychiatric and neurologic disorders. Its products include PD6735, the treatment of primary insomnia and additional indications, N-Substituted Analogs of Benztropine for the treatment of attention deficit hyperactivity disorder & Thiothalidomides and Hydroxythalidomides for the treatment of ALS and MS. Phase 2 Discovery was founded in 1998 and is headquartered in Cincinnati, OH.

RxDino LLC operates as a dermatology pharmaceutical company. The firm develops skin products for the treatment of dermatitis, rash, eczema, itchy, irritated skin, and allergies to plants and chemicals, such as poison ivy. It provides Over-the-counter topical hydrocortisone ointment with a formulation containing dehydroepiandrosterone as an emollient that enables hydrocortisone to be effective. The company is headquartered in Cincinnati, OH.